參考文獻

        1.Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in U.S. FDA fast-track process:bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9:1166-72.

        2.Junquera L, Gallefo L, et al. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysisof 21 cases. Am J Otolaryngol 2009; 30:390-5.

        3.Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonateassociated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dent 2010;19:29-38.

        4.Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668-77.

        5.Lindsay R, Cosman F. Osteoporosis. In: Brauwald E, Facui A, Kasper D, et al., eds. Harrison’s Principles of Internal

        Medicine 15thed. New York: McGraw-Hill, 2001:2226-37.

        6.Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003; 8:469-88.

        7.Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther 2005; 5:817-32.

        8.Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serumCTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397-410.

        9.Ruggiero SL, Mehrota B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management.

        Annu Rev Med 2009; 60:85-96.

 該文章轉載自：牙髓病學Endodontics公眾號 文章作者：劉賀